Shares of Solaris Resources Inc. (CVE:SLS – Get Free Report) traded down 2.7% during mid-day trading on Tuesday . The company traded as low as C$5.95 and last traded at C$6.15. 53,313 shares were traded during mid-day trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Price Performance
The firm has a 50-day moving average of C$6.15 and a 200 day moving average of C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than Solaris Resources
- What Does Downgrade Mean in Investing?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- High Flyers: 3 Natural Gas Stocks for March 2022
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
